# Efficacy of Verciguat in TR and RV Failure

Study · id `cardio:ct-nct07668739` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07668739](<https://clinicaltrials.gov/study/NCT07668739>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07668739

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07668739. Randomized; no masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07668739, source copy `cardio:ctgov-nct07668739-2026-06-25`, retrieved 2026-10-26)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07668739, source copy `cardio:ctgov-nct07668739-2026-06-25`, retrieved 2026-10-26)
- Primary completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07668739, source copy `cardio:ctgov-nct07668739-2026-06-25`, retrieved 2026-10-26)
- Completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07668739, source copy `cardio:ctgov-nct07668739-2026-06-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07668739, source copy `cardio:ctgov-nct07668739-2026-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07668739-2026-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Verciguat in TR and RV Failure
- Acronym: VERT-HF
- Condition: HFrEF
- Condition: Tricuspid Regurgitation (TR)
- Intervention (Drug): Vericiguat
- Lead sponsor: Daejeon St. Mary's hospital
- Lead sponsor class: OTHER
- Collaborator: Seoul St. Mary's Hospital
- Collaborator class: OTHER
- Collaborator: Uijeongbu St. Mary Hospital
- Collaborator class: OTHER
- Collaborator: Incheon St.Mary's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)
- Registry lists this organization as the lead sponsor: Daejeon St. Mary's hospital (`cardio:org-daejeon-st-mary-s-hospital`)
- Registry lists this organization as a collaborator: Seoul St. Mary's Hospital (`cardio:org-seoul-st-mary-s-hospital`)
- Registry lists this organization as a collaborator: Incheon St.Mary's Hospital (`cardio:org-incheon-st-mary-s-hospital`)

## Provenance

Content hash: a6c971e11f1fb4cb3c3166d168255fd0c0a48be2ae14268e3e6ad8437a263c57
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
